SCHEMBL24807720

SCHEMBL24807720

CC(C)(C)OC(=O)NCc1nc2cc(Cl)ccc2c(=O)[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ POLB P06746 2/20 0.49
▸ GAA P10253 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX12 P18054 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ CACNA1H O95180 1/20 0.45
▸ CACNA1B Q00975 1/20 0.45
▸ CACNA1C Q13936 1/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ PDE5A O76074 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ PRMT5 O14744 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149629 0.85 CACNA1H (0.53) GAASMN1; SMN2CACNA1HCACNA1BCACNA1C
SCHEMBL15597730 0.84 TNKS2 (0.53) POLBGAAALDH1A1SMN1; SMN2RECQL
SCHEMBL15243340 0.83 CACNA1H (0.53) SMN1; SMN2CACNA1HCACNA1BCACNA1CTDP1
SCHEMBL29893017 0.81 KDM4C (0.54) ALDH1A1CACNA1HCACNA1BCACNA1C
SCHEMBL28097938 0.78 PIM1 (0.57) LMNAPOLBGAAALDH1A1HPGD
SCHEMBL19104694 0.76 LMNA (0.54) LMNAPOLBGAAALDH1A1ALOX12
SCHEMBL23522706 0.75 CACNA1G (0.62) LMNAGAASMN1; SMN2CACNA1HCACNA1B
SCHEMBL5649627 0.75 TRPA1 (0.42) LMNAPOLBGAAHPGDALOX12
SCHEMBL5649621 0.75 TRPA1 (0.42) LMNAPOLBGAAHPGDALOX12
SCHEMBL5649785 0.75 TRPA1 (0.42) LMNAPOLBGAAHPGDALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4359413-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-05-01 — — EP disclosed
US-20230116253-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-04-13 — — US disclosed
WO-2022271650-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-29 — — WO disclosed
WO-2022271650-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116253-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK LMNA 3577/4885POLB 3212/4885GAA 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback